Silvercrest Asset Management’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Silvercrest Asset Management’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-12,000	Closed	-$31K	–	565
2017 Q2	$31K	Hold	12,000	–	–	﹤0.01%	537
2017 Q1	$44K	Hold	12,000	–	–	﹤0.01%	568
2016 Q4	$58K	Hold	12,000	–	–	﹤0.01%	569
2016 Q3	$554K	Hold	12,000	–	–	0.01%	395
2016 Q2	$612K	Hold	12,000	–	–	0.01%	387
2016 Q1	$507K	Hold	12,000	–	–	0.01%	405
2015 Q4	$942K	Buy	+12,000	New	+$694K	0.01%	359

Other funds holding ISEE

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Silvercrest Asset Management's ISEE Position: Q3 2017 in Review

Silvercrest Asset Management sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2017, closing a stake of 12,000 shares — an estimated $31K sold.

Silvercrest Asset Management first reported a position in ISEE in Q4 2015 and held it in 7 quarters. The position peaked at $942K in Q4 2015. 67 funds tracked by Wall St. Rank hold ISEE as of Q3 2017.

Silvercrest Asset Management reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
Silvercrest Asset Management sold 12,000 IVERIC bio, Inc. Common Stock shares in Q3 2017, an estimated $31K.
Silvercrest Asset Management first reported a position in IVERIC bio, Inc. Common Stock in Q4 2015 and held it in 7 quarters.
Silvercrest Asset Management's IVERIC bio, Inc. Common Stock position peaked at $942K in Q4 2015.
67 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2017.

Based on Silvercrest Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.